Soleno Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

• Soleno Therapeutics Inc SLNO.OQ reported quarterly adjusted earnings of 80 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.27. The mean expectation of thirteen analysts for the quarter was for earnings of 71 cents per share. Wall Street expected results to range from -28 cents to $1.11 per share.

• Revenue was $91.73 million​; analysts expected $88.55 million.

• Soleno Therapeutics Inc's reported EPS for the quarter was 47 cents​.

• The company reported quarterly net income of $26.01 million.

• Soleno Therapeutics Inc shares had fallen by 15.4% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 91.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Soleno Therapeutics Inc is $114.00, about 65.6% above its last closing price of $39.16

This summary was machine generated from LSEG data February 25 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)